Eli Lilly and Company (LLY)vsMyriad Genetics Inc (MYGN)
LLY
Eli Lilly and Company
$1,131.42
-1.21%
HEALTHCARE · Cap: $1.01T
MYGN
Myriad Genetics Inc
$4.69
+6.59%
HEALTHCARE · Cap: $414.63M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 12871% more annual revenue ($72.25B vs $557.00M). LLY leads profitability with a 35.0% profit margin vs -41.3%. MYGN appears more attractively valued with a PEG of 1.24. LLY earns a higher WallStSmart Score of 76/100 (B+).
LLY
Strong Buy76
out of 100
Grade: B+
MYGN
Hold44
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
+89.7%
Fair Value
$46.95
Current Price
$4.69
$42.26 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 32.4x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -118.5% — below average capital efficiency
Revenue declined 20.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : MYGN
The strongest argument for MYGN centers on Price/Book. PEG of 1.24 suggests the stock is reasonably priced for its growth.
Bear Case : LLY
The primary concerns for LLY are PEG Ratio, Debt/Equity, P/E Ratio. A P/E of 40.2x leaves little room for execution misses.
Bear Case : MYGN
The primary concerns for MYGN are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
LLY profiles as a growth stock while MYGN is a turnaround play — different risk/reward profiles.
MYGN carries more volatility with a beta of 1.64 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 44/100), backed by strong 35.0% margins and 55.5% revenue growth. MYGN offers better value entry with a 89.7% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Myriad Genetics Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Myriad Genetics, Inc., a molecular diagnostics company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company is headquartered in Salt Lake City, Utah.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?